Welcome to our dedicated page for GSK plc SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reported that an additional 96,525 ordinary shares of 31¼ pence each have been admitted to trading on the London Stock Exchange Main Market. These shares were issued under existing block listings connected to the GlaxoSmithKline plc Share Save Plan 2012 and 2022.
Following this admission, the total number of GSK ordinary shares admitted to trading is 4,316,176,278, fully fungible with existing shares. The notification covers activity between 23 January 2026 and 20 March 2026 and was signed by Company Secretary Victoria Whyte.
GSK plc reported that its investigational B7-H3‑targeted antibody‑drug conjugate risvutatug rezetecan (Ris‑Rez) has received Orphan Drug Designation in Japan for treating small‑cell lung cancer. The decision by Japan's Ministry of Health, Labour and Welfare is based on preliminary phase I ARTEMIS‑001 data showing durable responses in extensive‑stage small‑cell lung cancer.
This is the sixth global regulatory designation for Ris‑Rez, which is being developed for multiple solid tumours, including lung, prostate and colorectal cancers. GSK has already started a global phase III trial (NCT07099898) in relapsed extensive‑stage small‑cell lung cancer, which began in August 2025, alongside prior US FDA and European EMA designations.
GSK plc reports that on 20 March 2026 it repurchased 560,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 1,940.50p to 1,967.50p per share, with a volume‑weighted average price of 1,953.58p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back 13,331,521 ordinary shares. After this transaction, it holds 253,222,615 shares in treasury and has 4,062,953,663 ordinary shares in issue excluding treasury, which is also the total number of voting rights. Treasury shares represent 6.23% of voting rights.
GSK plc reports that it bought back 650,000 ordinary shares on 19 March 2026 through BNP Paribas as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were acquired at a volume‑weighted average price of 1,954.04p, within a range of 1,944.50p to 1,975.50p per share.
The shares will be held as treasury shares. Since 17 February 2026, GSK has purchased 12,771,521 ordinary shares under this programme. After this transaction, the company holds 252,662,615 shares in treasury and has 4,063,508,150 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.22% of voting rights, a figure shareholders can use when assessing disclosure thresholds.
GSK plc reports that the US FDA has approved Lynavoy (linerixibat) to treat cholestatic pruritus in adult patients with primary biliary cholangitis (PBC). Lynavoy is an ileal bile acid transporter (IBAT) inhibitor and is the first medicine approved in the US specifically for this indication.
The approval is supported by the phase III GLISTEN trial, which met its primary and key secondary endpoints, showing significant, rapid (by week two) and sustained (over 24 weeks) reductions in itch and itch-related sleep interference versus placebo. The most common side effects were diarrhoea and abdominal pain, generally mild to moderate.
GSK previously signed a licence agreement for Alfasigma S.p.A. to acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, with this transaction still subject to customary regulatory clearances. Regulatory reviews for linerixibat are also underway in the EU, UK, Canada and China, and the drug has Orphan Drug Designation in the US and Japan and priority review in China.
GSK plc reports that, acting through BNP Paribas, it purchased 836,000 of its ordinary shares on 18 March 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at a volume-weighted average price of 1,980.45p, within a range from 1,946.00p to 2,013.00p per share.
The purchased shares will be held as treasury shares. Since 17 February 2026, the company has repurchased a total of 12,121,521 ordinary shares. Following the latest transaction, GSK will hold 252,012,615 ordinary shares in treasury and have 4,064,158,150 ordinary shares in issue, which is also the total number of voting rights.
GSK confirms that, in line with DTR 5.5.1R, the voting rights attributable to treasury shares represent 6.20% of the total. The filing also provides detailed trade-by-trade data, including prices and volumes across London Stock Exchange and Cboe Europe order books (CHIX and BATE).
GSK plc filed a report describing a small insider share purchase. Chief People Officer Diana Conrad acquired American Depositary Shares under a GSK pension plan. She bought 12.430 ADS at a price of $54.4100 per ADS on 2026-03-16 on the New York Stock Exchange.
GSK plc reports that, through BNP Paribas, it repurchased 732,112 ordinary shares of 31¼ pence each on 17 March 2026 as part of its existing share buyback programme. The shares were bought at prices between 2,002.00p and 2,036.00p, with a volume‑weighted average of 2,016.45p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 11,285,521 ordinary shares. After this transaction, it holds 251,176,615 shares in treasury and has 4,064,994,150 shares in issue, which is also the total number of voting rights. Treasury shares represent 6.18% of voting rights.
GSK plc reported that senior executive Maya Martinez-Davis, President, acquired notional American Depositary Shares through the GSK Executive Supplemental Savings Plan. The transaction involved 129.152 ADS at a price of $53.3900 per ADS on 2026-03-13 on the New York Stock Exchange.
These are plan-related notional ADS rather than a standard open-market purchase, reflecting additional equity-linked compensation within her executive savings account.
GSK plc reports that it repurchased 628,000 ordinary shares on 16 March 2026 under its existing share buyback programme, acting through BNP Paribas. The shares were bought at prices between 2,026.00p and 2,052.00p per share, with a volume‑weighted average price of 2,035.82p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back a total of 10,553,409 ordinary shares. After this transaction, GSK holds 250,444,503 shares in treasury and has 4,065,726,262 ordinary shares in issue, all carrying voting rights.
The total number of voting rights in GSK is stated as 4,065,726,262, and the company notes that treasury shares represent 6.16% of its voting rights, a figure shareholders can use when assessing notification thresholds under UK disclosure rules.